Home
News
Create
Screeners
Insights
Parmax Pharma
30.
00
-1.00
(-3.23%)
Market Cap
₹11.23 Cr
PE Ratio
-2.29
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-3.23%
1M
+18.95%
6M
-4.28%
1Y
-28.61%
5Y
-44.80%
View Company Insights
Latest news about Parmax Pharma
Parmax Pharma Re-appoints Dr. Umang Gosalia as Managing Director for Five Years
1 day ago
Yesterday
Parmax Pharma Limited's Board of Directors approved the re-appointment of Dr. Umang Gosalia as Managing Director for five years from June 28, 2026 to June 27, 2031, subject to shareholder approval. Dr. Gosalia, who holds a Ph.D. in Organic Chemistry and has been with the company since 2016, currently oversees all production activities and brings over 15 years of chemistry experience to the role.
Parmax Pharma Limited Files SEBI Compliance Certificate for Q4 FY26 Dematerialization Process
Apr 17, 2026
Parmax Pharma Limited Appoints Ms. Bhakti Aghera as Company Secretary and Compliance Officer
Mar 25, 2026
Parmax Pharma Reports Q3 FY26 Net Loss of Rs 73.19 Lakh, Revenue Drops 31.2% YoY
Feb 15, 2026
Parmax Pharma Reports Significant Loss of Rs 284.29 Crore for H1 2025
Nov 17, 2025
More news about Parmax Pharma
05
Sept 25
Parmax Pharma Reports Mixed Financial Results for FY 2023 with Revenue Decline
Parmax Pharma Limited's FY 2023 results show a decline in performance. Annual revenue decreased to Rs 154,243.45 thousand from Rs 182,511.20 thousand in FY 2022. The company reported a net loss of Rs 1,040.68 thousand, compared to a profit of Rs 1,415.13 thousand in the previous year. Quarterly revenue for Q4 2023 was Rs 63,819.33 thousand, down from Rs 70,879.78 thousand in Q4 2022. However, the company posted a quarterly net profit of Rs 1,729.60 thousand. Total assets stood at Rs 176,126.31 thousand as of March 31, 2023. The statutory auditors issued an unmodified opinion on the financial results.
Parmax Pharma
30.
00
-
1.
00
(-
3.
23
%)
1 Year Returns:
-28.61%
Industry Peers
Sun Pharmaceutical
1,808.30
(+
1.
66
%)
Divis Laboratories
6,502.50
(-
0.
48
%)
Torrent Pharmaceuticals
4,185.10
(-
1.
10
%)
Dr Reddys Laboratories
1,322.90
(-
0.
52
%)
Cipla
1,309.60
(-
0.
61
%)
Lupin
2,305.20
(-
0.
27
%)
Mankind Pharma
2,246.70
(-
0.
45
%)
Zydus Life Science
891.90
(-
2.
08
%)
Aurobindo Pharma
1,389.50
(-
0.
52
%)
Glenmark Pharmaceuticals
2,406.30
(-
0.
31
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO